Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Question on Company Buying

Question on Company Buying

posted on Mar 14, 2008 11:56AM

I've never quite understood,

 

considering PTSC had an announced share buyback plan that specified that with each license, they would purchase a minumum of 10% worth of shares based on the license revenue generated,

 

why they have been precluded from buying back shares during the period since the J3 settlements.

 

I do understand that they had announced that they had suspended the share buyback plan "for now", and I have attributed this prohibition on purchasing to that announcement, however, if that announcement had never been made, since they had a preannounced and specifically enumerated plan of repurchasing, they should have been allowed to continue to repurchase shares regardless of unannounced material information.  That afterall is one of the main reasons you preannounce a share purchasing or selling plan.

 

Assuming my understanding to be correct, I think the BOD/Turley made an error in suspending the share buyback plan prior to the J3 settlement as it would have allowed them to keep the buybacks at the minimum levels, AND maintain 90% of the proceeds for M&A activities, a win-win in my opinion.

Share
New Message
Please login to post a reply